Mirati Therapeutics - MRTX Stock Forecast, Price & News

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRTX shares.
View MRTX analyst ratings or view top-rated stocks.

13 brokers have issued 12 month price objectives for Mirati Therapeutics' shares. Their MRTX share price forecasts range from $72.00 to $188.00. On average, they predict the company's stock price to reach $110.64 in the next year. This suggests a possible upside of 21.2% from the stock's current price.
View analysts price targets for MRTX or view top-rated stocks among Wall Street analysts.

Mirati Therapeutics' stock was trading at $146.69 at the beginning of the year. Since then, MRTX shares have decreased by 37.8% and is now trading at $91.27.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our MRTX earnings forecast.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) released its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($1.55) EPS for the quarter, topping the consensus estimate of ($2.87) by $1.32. The biotechnology company had revenue of $71.79 million for the quarter, compared to analyst estimates of $1.41 million. Mirati Therapeutics had a negative net margin of 6,253.81% and a negative trailing twelve-month return on equity of 60.40%. The business's quarterly revenue was up 528.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.96) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Mirati Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.21%), Perceptive Advisors LLC (4.84%), BlackRock Inc. (4.22%), Armistice Capital LLC (3.30%), State Street Corp (2.73%) and Price T Rowe Associates Inc. MD (1.98%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, Henry J Fuchs, Isan Chen, Jamie Christensen, Julie M Cherrington, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends.

Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRTX stock can currently be purchased for approximately $91.27.

Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $5.26 billion and generates $72.09 million in revenue each year. The biotechnology company earns $-581,780,000.00 in net income (profit) each year or ($13.39) on an earnings per share basis.

The company employs 413 workers across the globe.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.